News

Highlights Total operating expenses increased $2,225 or less than 1% vs. the prior year’s comparable quarter. Operating loss for the quarter was $61,060 vs. $62,913 for the prior

Archimedes Pharma, a UK-based specialty pharmaceutical company, has reported new positive headline Phase III results for NasalFent, the company’s differentiated fentanyl citrate nasal spray, developed for the rapid

Daiichi Sankyo has reported blinded one-year blood pressure reduction data from the ongoing study Roadmap, the first-ever large-scale clinical trial, being conducted in 19 European countries to evaluate

Halozyme, a biopharmaceutical company, has reported a net loss of $14.72m, or $0.18 per share for the first quarter of 2009, compared to a net loss of $9.95m,

The PATH Malaria Vaccine initiative will provide funding, whereas scientists from the US National Institute of Allergy and Infectious Diseases (NIAID) will provide expertise to the project. The

Takeda Pharmaceutical Company has reported that it will integrate its wholly owned subsidiaries Takeda Ireland Limited or TIL and Takeda Pharma Ireland Limited or TPI into a single

Canadian biopharmaceutical company MethylGene has reported a net loss of C$6.1m or C$0.17 per share for the first quarter ended March 31, 2009 compared to a net loss

Inhibitex, a biopharmaceutical company, has initiated a Phase II clinical trial with FV-100, its oral antiviral compound in clinical development for the treatment of herpes zoster. The Phase

French molecular diagnostic company Ipsogen has launched the MapQuant Dx HR test in Europe. The MapQuant Dx testing solution has been developed under the Innovation Support Program of